Clinically, this suggests that combining ferroptosis inducers with mTOR or HIF2α inhibitors-and potentially targeting PLIN2-could provide a multifaceted therapeutic strategy against advanced ccRCC. Here, MTOR is linked to nonpapillary renal cell carcinoma.